[Gemfibrozil reduces elevated lipoprotein (a) levels in hypercholesterolemic patients]

Area of Science:

• Cardiology
• Pharmacology
• Lipid Metabolism

Background:

• Hypercholesterolemia is a significant risk factor for cardiovascular disease.
• Elevated lipoprotein(a) [Lp(a)] levels are independently associated with increased cardiovascular risk.
• Current treatments for hypercholesterolemia primarily focus on LDL-C reduction.

Purpose of the Study:

• To compare the efficacy of gemfibrozil and lovastatin in managing hypercholesterolemia.
• To investigate the effects of gemfibrozil and lovastatin on lipoprotein(a) [Lp(a)] levels.
• To evaluate lipid profile changes in patients with elevated cholesterol and Lp(a).

Main Methods:

• A randomized study involving 27 patients with hypercholesterolemia and elevated Lp(a).
• Participants received either gemfibrozil (1200 mg/day) or lovastatin (40-80 mg/night) for 12 weeks.
• Lipid profiles and Lp(a) levels were assessed at baseline, 4 weeks, and 12 weeks.

Main Results:

• Gemfibrozil significantly reduced total cholesterol (TC), LDL-C, triglycerides (TG), and Lp(a), while increasing HDL-C.
• Lovastatin significantly reduced TC, LDL-C, and TG but had no significant effect on Lp(a) levels.
• Gemfibrozil demonstrated a notable -25% reduction in Lp(a) levels.

Conclusions:

• Gemfibrozil offers a dual benefit by improving the overall lipid profile and effectively lowering Lp(a) levels.
• Lovastatin is effective for LDL-C and TG reduction but does not influence Lp(a) levels.
• Gemfibrozil may be a preferred option for patients with hypercholesterolemia and elevated Lp(a).